KXV01 injection for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This early-stage trial tests KXV01, a personalized cancer treatment made from your own immune cells, for advanced solid tumors that have not responded to standard treatment. The goal is to see if it can help control your cancer and learn about its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Advanced solid tumor (including osteosarcoma or sarcoma) that has failed standard treatment or has no standard option
- Expected to live more than 6 months
- Good overall health status (ECOG 0–1: able to do most normal activities)
- Able to provide a tumor sample from which personalized immune cells can be grown
- Willing to use contraception for at least 12 months during and after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy that uses your own immune cells (T-cells) specially modified to target your tumor. It is for people with advanced solid tumors who have run out of standard treatment options.
This trial tests a personalized treatment made from your own immune cells (T-cells) that are modified to attack your tumor. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.
This trial tests an experimental cell treatment called GK01 for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if it can help shrink tumors or slow their growth.
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
This trial tests a new cell treatment called GK01 for people with advanced lung cancer or esophageal cancer that has not responded to standard treatments. The study aims to see if this therapy can help shrink tumors or slow the cancer's growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.